Xeltis, a privately held medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery, has announced that it has finished enrollment in a five-patient feasibility study of implantable products intended to enable for the first time the…
Xeltis completes enrollment for study of spontaneous tissue growth technology
Friday, February 28, 2014
Xeltis completes enrollment for study of spontaneous tissue growth technology
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment